Anti-AIDS Agents 81. Design, Synthesis, and Structure−Activity Relationship Study of Betulinic Acid and Moronic Acid Derivatives as Potent HIV Maturation Inhibitors
- 23 March 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (8) , 3133-3141
Abstract
In our continuing study of triterpene derivatives as potent anti-HIV agents, different C-3 conformationally restricted betulinic acid (BA, 1) derivatives were designed and synthesized in order to explore the conformational space of the C-3 pharmacophore. 3-O-Monomethylsuccinyl-betulinic acid (MSB) analogues were also designed to better understand the contribution of the C-3′ dimethyl group of bevirimat (2), the first-in-class HIV maturation inhibitor, which is currently in phase IIb clinical trials. In addition, another triterpene skeleton, moronic acid (MA, 3), was also employed to study the influence of the backbone and the C-3 modification toward the anti-HIV activity of this compound class. This study enabled us to better understand the structure−activity relationships (SAR) of triterpene-derived anti-HIV agents and led to the design and synthesis of compound 12 (EC50: 0.0006 μM), which displayed slightly better activity than 2 as a HIV-1 maturation inhibitor.Keywords
This publication has 22 references indexed in Scilit:
- Anti-AIDS Agents. 78. Design, Synthesis, Metabolic Stability Assessment, and Antiviral Evaluation of Novel Betulinic Acid Derivatives as Potent Anti-Human Immunodeficiency Virus (HIV) AgentsJournal of Medicinal Chemistry, 2009
- Anti-AIDS agents 73: Structure–activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinyl-betulinic acid derivativesBioorganic & Medicinal Chemistry Letters, 2007
- Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus InfectionAntimicrobial Agents and Chemotherapy, 2007
- Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2007
- Multiple-Dose Pharmacokinetics and??Safety of Bevirimat, a??Novel??Inhibitor??of??HIV Maturation,??in??Healthy??VolunteersClinical Pharmacokinetics, 2007
- The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIVExpert Opinion on Investigational Drugs, 2005
- Anti-Human Immunodeficiency Virus Activity of YK-FH312 (a Betulinic Acid Derivative), a Novel Compound Blocking Viral MaturationAntimicrobial Agents and Chemotherapy, 2001
- Drug Interactions in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1996
- Betulinic Acid and Dihydrobetulinic Acid Derivatives as Potent Anti-HIV AgentsJournal of Medicinal Chemistry, 1996
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995